AUS
NZ
UK
CA
USA
IND
Highlights
- Major firms expanded their positions in Avid Bioservices over consecutive quarters
- Price T Rowe and JPMorgan Chase increased their exposure significantly
- The company maintains a key presence on NASDAQ and S&P SmallCap 600
Positioned within the NASDAQ Composite, Avid Bioservices contributes to the biotech sector through its end-to-end manufacturing support for biologic therapies.
Quarterly Changes by Prominent Firms
Recent quarters have seen a marked increase in institutional activity related to Avid Bioservices. Price T Rowe Associates Inc. MD expanded its position during the final quarter of the last calendar year. This shift came alongside other movements from established firms, reflecting continued institutional attention.
During an earlier period, JPMorgan Chase & Co. made a substantial adjustment to its position in the company. This activity added to the visibility of Avid Bioservices within the institutional landscape. Similarly, Franklin Resources also adjusted its stance, reinforcing the broader trend of engagement from longstanding financial entities.
Further Institutional Interest and Positioning
Additional momentum emerged as SG Americas Securities LLC raised its stake in the company. These strategic actions indicate that institutions have closely monitored Avid Bioservices in relation to broader sectoral movements.
Current Market
Avid Bioservices trades on the NASDAQ exchange and is also part of the S&P SmallCap 600 index. Its share price activity has shown consistency, with average price trends remaining steady over medium- and long-term periods. The company has demonstrated resilience across both its short-term and long-term moving averages.
The firm carries a high debt-to-equity ratio, along with financial ratios that reflect its capital structure and liquidity position. These figures provide insights into how the business manages its financial obligations and short-term operational capacity.
Company Services and Sector Relevance
Operating as a full-service CDMO, Avid Bioservices delivers end-to-end support in biologics manufacturing. Offerings include process development, formulation, packaging, and compliance support for therapeutic manufacturing. These services cater to both clinical-stage and commercial-stage pharmaceutical needs.
The organization’s infrastructure supports advanced biologic compounds and regulatory adherence across therapeutic segments. It remains a key participant in the contract-based pharmaceutical manufacturing ecosystem, with a defined focus on quality, timelines, and regulatory excellence.
Market Standing and Sector Activity
Avid Bioservices continues to operate within the context of expanding biopharmaceutical services. The firm's role in clinical production pipelines and its alignment with market standards place it at the center of biologics manufacturing in the United States.
With multiple institutional entities altering their engagement, Avid Bioservices maintains its relevance within the biopharmaceutical sector. Listed on both NASDAQ and the S&P SmallCap 600, it reflects the structural dynamics that influence the contract manufacturing market.
